Key result
Self-expanding TAVR proves noninferior to surgery for death or disabling stroke in low-risk severe AS.
Why the study?
Does TAVR with a self-expanding bioprosthesis prevent the composite of death or disabling stroke compared to surgical aortic-valve replacement in patients with severe aortic stenosis at low surgical risk?
Does TAVR with a self-expanding bioprosthesis prevent the composite of death or disabling stroke compared to surgical aortic-valve replacement in patients with severe aortic stenosis at low surgical risk?
In patients with severe aortic stenosis at low surgical risk, TAVR with a self-expanding bioprosthesis was noninferior to surgery for the composite of death or disabling stroke at 24 months.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“[The study] provides robust, long-term evidence supporting the use of balloon-expandable TAVR in appropriately selected low-risk patients and reinforces the current guideline recommendations.”
Supports TAVR as alternative to surgery in low-risk severe AS; extends high-risk evidence to this population.
In patients with severe aortic stenosis who were at low surgical risk, TAVR with a self-expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite end point of death or disabling stroke at 24 months. (Funded by Medtronic; ClinicalTrials.gov number, NCT02701283.).
No takes yet. Share an insight, caveat, or question.
Popma et al. (2019) studied this question. TAVR with a self-expanding bioprosthesis was noninferior to surgery for death or disabling stroke at 24 months in low-risk patients with severe aortic stenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: